{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:25:24Z","timestamp":1791411924744,"version":"4.3.3"},"reference-count":122,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1038\/ajg.2010.392","type":"journal-article","created":{"date-parts":[[2010,11,2]],"date-time":"2010-11-02T11:43:19Z","timestamp":1288698199000},"page":"199-212","source":"Crossref","is-referenced-by-count":312,"title":["The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?"],"prefix":"10.14309","volume":"106","author":[{"given":"Geert R","family":"D'Haens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D R","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Gassull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Herfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan W","family":"Hommes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"L\u00f6fberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Quary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Watermayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret","family":"Lashner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"L\u00e9mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Plevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Targan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210210","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-5-20210210","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohns disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R3-5-20210210","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC-I trial.","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"R4-5-20210210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial.","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"R5-5-20210210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohns disease.","volume":"357","author":"Schreiber","year":"2007","journal-title":"New Engl J Med"},{"key":"R6-5-20210210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohns disease.","volume":"357","author":"Sandborn","year":"2007","journal-title":"New Engl J Med"},{"key":"R7-5-20210210","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohns disease.","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-5-20210210","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohns disease.","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"key":"R9-5-20210210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohns disease.","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"R10-5-20210210","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/gast.2000.18144","article-title":"A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohns disease.","volume":"119","author":"Markowitz","year":"2000","journal-title":"Gastroenterology"},{"key":"R11-5-20210210","first-page":"147","article-title":"Early Crohns disease shows high levels of remission to therapy with adalimumab: subanalysis of CHARM.","volume":"132","author":"Schreiber","year":"2007","journal-title":"Gastroenterology"},{"key":"R12-5-20210210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease: an open randomised trial.","volume":"371","author":"DHaens","year":"2008","journal-title":"Lancet"},{"key":"R13-5-20210210","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohns disease in children.","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"R15-5-20210210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.crohns.2007.11.002","article-title":", for the European Crohns and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of ulcerative colitis: current management.","volume":"2","author":"Travis","year":"2008","journal-title":"J Crohns Colitis"},{"key":"R16-5-20210210","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.14309\/00000434-200809001-01116","article-title":"Safety of infliximab and other Crohns disease therapies: TREATTM registry data with 24575 patient-years of follow-up.","volume":"103","author":"Lichtenstein","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R17-5-20210210","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease.","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"R18-5-20210210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":", on behalf of the European Crohns Colitis Organisation (ECCO). European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.","volume":"3","author":"Rahier","year":"2009","journal-title":"J Crohns Colitis"},{"key":"R19-5-20210210","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National co-operative Crohns disease study group: results of drug treatment.","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"R20-5-20210210","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohns disease. Canadian Inflammatory Bowel Disease Study Group.","volume":"331","author":"Greenberg","year":"1994","journal-title":"New Engl J Med"},{"key":"R21-5-20210210","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohns disease.","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"key":"R22-5-20210210","first-page":"CD002913","article-title":"Budesonide for maintenance of remission in Crohns disease.","volume":"1","author":"Benchimol","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-5-20210210","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1572-0241.2005.41992.x","article-title":"Budesonide for maintenance of remission in patients with Crohns disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.","volume":"100","author":"Sandborn","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R24-5-20210210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"R25-5-20210210","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohns disease.","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"R26-5-20210210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2036.2006.02974.x","article-title":"The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort.","volume":"24","author":"Ho","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-5-20210210","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","article-title":"Clinical biological and endoscopic picture of attacks of Crohns disease. Evolution on prednisolone Groupe dEtude Therapeutique des Affections Inflammatoires Digestives.","volume":"98","author":"Modigliani","year":"1990","journal-title":"Gastroenterology"},{"key":"R28-5-20210210","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Group I mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.","volume":"133","author":"Froslie","year":"2007","journal-title":"Gastroenterology"},{"key":"R29-5-20210210","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.mib.0000235835.32176.85","article-title":"A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohns disease and ulcerative colitis.","volume":"12","author":"Tung","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"R30-5-20210210","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S1873-9946(09)60210-5","article-title":"Predictive factors for a mild course of Crohns disease.","volume":"3","author":"Bokemeyer","year":"2009","journal-title":"J Crohns Colitis"},{"key":"R31-5-20210210","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/0016-5085(90)90324-T","article-title":"Effect of cigarette smoking on recurrence of Crohns disease.","volume":"98","author":"Sutherland","year":"1990","journal-title":"Gastroenterology"},{"key":"R32-5-20210210","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/0016-5085(93)91068-S","article-title":"Intestinal cancer risk and mortality in patients with Crohns disease.","volume":"105","author":"Munkholm","year":"1993","journal-title":"Gastroenterology"},{"key":"R33-5-20210210","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/0016-5085(92)91163-X","article-title":"Colorectal cancer risk and mortality in patients with ulcerative colitis.","volume":"103","author":"Langholz","year":"1992","journal-title":"Gastroenterology"},{"key":"R34-5-20210210","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/gast.2002.33632","article-title":"Mortality and causes of death in Crohns disease: follow-up of a population-based cohort in Copenhagen County, Denmark.","volume":"122","author":"Jess","year":"2002","journal-title":"Gastroenterology"},{"key":"R35-5-20210210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ibd.21007","article-title":"Overall and cause-specific mortality in Crohns disease: a meta-analysis of population-based studies.","volume":"16","author":"Duricova","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"R36-5-20210210","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00042737-199810000-00001","article-title":"Clinical pattern of corticosteroid dependent Crohns disease.","volume":"10","author":"Franchimont","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R37-5-20210210","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1572-0241.2006.00463.x","article-title":"Factors associated with the development of intestinal strictures or obstructions in patients with Crohns disease.","volume":"101","author":"Lichtenstein","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R38-5-20210210","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of Crohns disease.","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"key":"R39-5-20210210","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/00365520801957149","article-title":"Predictors of severe Crohns disease.","volume":"43","author":"Loly","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"R40-5-20210210","first-page":"17","article-title":"Validation of predictors of 5-year disabling CD in a population-based cohort from Olmsted County, Minnesota 1983-1996.","volume":"132","author":"Seksik","year":"2007","journal-title":"Gastroenterology"},{"key":"R41-5-20210210","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/gast.2002.35393","article-title":"Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohns disease.","volume":"123","author":"Abreu","year":"2002","journal-title":"Gastroenterology"},{"key":"R42-5-20210210","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cgh.2009.05.001","article-title":"Genetic risk profiling and prediction of disease course in Crohns disease patients.","volume":"7","author":"Henckaerts","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R43-5-20210210","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.sla.0000186173.14696.ea","article-title":"Crohns disease patients carrying Nod2CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence.","volume":"242","author":"Alvarez-Lobos","year":"2005","journal-title":"Ann Surg"},{"key":"R44-5-20210210","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1053\/gast.2002.34020","article-title":"The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohns disease.","volume":"122","author":"Radlmayr","year":"2002","journal-title":"Gastroenterology"},{"key":"R45-5-20210210","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2036.2004.01967.x","article-title":"Mutations in the NOD2CARD15 gene in Crohns disease are associated with ileocecal resection and are a risk factor for reoperation.","volume":"19","author":"Buning","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R46-5-20210210","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2006.108043","article-title":"New serological markers in inflammatory bowel disease are associated with complicated disease behaviour.","volume":"56","author":"Ferrante","year":"2007","journal-title":"Gut"},{"key":"R47-5-20210210","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.3748\/wjg.v16.i21.2609","article-title":"Role of genetics in prediction of disease course and response to therapy.","volume":"16","author":"Vermeire","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R48-5-20210210","first-page":"15","article-title":"Belgian IBD Research Group. Treatment of small bowel subocclusive Crohns disease with infliximab: an open pilot study.","volume":"70","author":"Louis","year":"2007","journal-title":"Acta Gastroenterol Belg"},{"key":"R49-5-20210210","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"SONIC study group. Infliximab, azathioprine, or combination therapy for Crohns disease.","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"R50-5-20210210","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohns disease: meta-analysis of placebo-controlled trials.","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R51-5-20210210","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.","volume":"62","author":"Watson","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R52-5-20210210","first-page":"25","article-title":"Is anti-TNF therapy always prohibited in patients with inflammatory bowel disease and previous malignancy?","volume":"33","author":"Lust","year":"2009","journal-title":"Pract Gastroenterol"},{"key":"R53-5-20210210","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","article-title":"Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.","volume":"66","author":"Lozeron","year":"2009","journal-title":"Arch Neurol"},{"key":"R54-5-20210210","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R55-5-20210210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.crohns.2009.09.009","article-title":", for the European Crohns and Colitis Organisation. European evidence-based Consensus on the diagnosis and management of Crohns disease 2009: special situations.","volume":"4","author":"Van Assche","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R56-5-20210210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ibd.20608","article-title":"Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohns disease: a randomized, double-blind, placebo-controlled pilot study.","volume":"15","author":"Thia","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R57-5-20210210","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1046\/j.1365-2036.2003.01793.x","article-title":"Antibiotics and azathioprine for the treatment of perianal fistulas in Crohns disease.","volume":"18","author":"Dejaco","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R58-5-20210210","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohns disease with 6-mercaptopurine. A long-term, randomized, double-blind study.","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"key":"R59-5-20210210","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1365-2036.2004.02247.x","article-title":"Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohns disease with infliximab: a double-blind placebo-controlled study.","volume":"20","author":"West","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R60-5-20210210","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9270(02)05909-9","article-title":"Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohns disease.","volume":"98","author":"Van Assche","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R61-5-20210210","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s10350-006-0656-5","article-title":"Fistulating anal Crohns disease: results of combined surgical and infliximab treatment.","volume":"49","author":"Hyder","year":"2006","journal-title":"Dis Colon Rectum"},{"key":"R62-5-20210210","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1007\/s10620-008-0545-y","article-title":"Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohns disease.","volume":"54","author":"Tougeron","year":"2009","journal-title":"Dig Dis Sci"},{"key":"R63-5-20210210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2007.11.001","article-title":"Vermeire, et al., for the European Crohns and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis.","volume":"2","author":"Stange","year":"2008","journal-title":"J Crohns Colitis"},{"key":"R64-5-20210210","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"key":"R65-5-20210210","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"R66-5-20210210","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/ibd.20899","article-title":"Incidence and clinical significance of immunogenicity to infliximab in Crohns disease: a critical systematic review.","volume":"15","author":"Cassinnotti","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R67-5-20210210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","article-title":"Remission in patients with Crohns disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.","volume":"99","author":"Lichtenstein","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R68-5-20210210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200207000-00001","article-title":"Infliximab improves quality of life in patients with Crohns disease.","volume":"8","author":"Lichtenstein","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"R69-5-20210210","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohns disease: results from the CHARM study.","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"R70-5-20210210","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohns disease.","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"R71-5-20210210","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohns disease.","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"key":"R72-5-20210210","first-page":"S5","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis.","volume":"4","author":"Reinisch","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R73-5-20210210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","article-title":"Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.","volume":"30","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R74-5-20210210","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.14309\/00000434-200609001-01173","article-title":"Sustained clinical remission in patients with moderate to severe Crohns disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressant therapy.","volume":"101","author":"Hanauer","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R76-5-20210210","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohns disease treated with scheduled infliximab maintenance: a randomized trial.","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"R77-5-20210210","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohns disease patients: a randomized placebo-controlled trial.","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"R81-5-20210210","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.gastro.2008.10.051","article-title":"Infliximab prevents Crohns disease recurrence after ileal resection.","volume":"136","author":"Regueiro","year":"2009","journal-title":"Gastroenterology"},{"key":"R82-5-20210210","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohns disease.","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R83-5-20210210","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1365-2036.2003.01574.x","article-title":"An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohns disease.","volume":"17","author":"Arnott","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R84-5-20210210","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/gast.2002.35390","article-title":"Predictors of response to infliximab in patients with Crohns disease.","volume":"123","author":"Parsi","year":"2002","journal-title":"Gastroenterology"},{"key":"R85-5-20210210","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00054725-200407000-00004","article-title":"Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohns disease.","volume":"10","author":"Fefferman","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R86-5-20210210","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10350-004-6611-4","article-title":"Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohns disease: a single center experience.","volume":"46","author":"Topstad","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"R87-5-20210210","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"R88-5-20210210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab therapy in acute ulcerative colitis.","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"R89-5-20210210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ibd.20054","article-title":"Predictors of early response to infliximab in patients with ulcerative colitis.","volume":"13","author":"Ferrante","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R90-5-20210210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","article-title":"Long-term outcome after infliximab for refractory ulcerative colitis.","volume":"3","author":"Ferrante","year":"2008","journal-title":"J Crohns Colitis"},{"key":"R91-5-20210210","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gut.2005.069476","article-title":"Laboratory markers in IBD: useful, magic, or unnecessary toys?","volume":"55","author":"Vermeire","year":"2006","journal-title":"Gut"},{"key":"R92-5-20210210","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment, but not with -308 TNF gene polymorphism.","volume":"37","author":"Louis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"R93-5-20210210","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohns disease.","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"R94-5-20210210","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohns disease: results from a single-centre cohort.","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"R95-5-20210210","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/gast.2001.23966","article-title":"ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohns disease.","volume":"120","author":"Taylor","year":"2001","journal-title":"Gastroenterology"},{"key":"R96-5-20210210","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1572-0241.2002.05689.x","article-title":"Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohns disease.","volume":"97","author":"Esters","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R97-5-20210210","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease.","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"R98-5-20210210","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohns disease.","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R99-5-20210210","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity of long-term outcome of adalimumab therapy in Crohns disease.","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"R100-5-20210210","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody levels in patients with inflammatory bowel disease.","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"R101-5-20210210","first-page":"A146","article-title":"Hospitalized steroid refractory ulcerative colitis treated with infliximab: a 2 year follow-up.","volume":"132","author":"Gustavsson","year":"2007","journal-title":"Gastroenterology"},{"key":"R102-5-20210210","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohns disease previously treated with infliximab: a randomized trial (GAIN).","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"R103-5-20210210","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohns disease and secondary failure to infliximab.","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R104-5-20210210","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2036.2009.04130.x","article-title":"The efficacy and safety of a third anti-TNF monoclonal antibody in Crohns disease after failure of two other anti-TNF antibodies.","volume":"31","author":"Allez","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R105-5-20210210","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.14309\/00000434-200809001-01069","article-title":"Adalimumab effectiveness in TNF-antagonist-naive patients and in infliximab non-responders with Crohns disease: results from the CARE study.","volume":"103","author":"Lofberg","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R106-5-20210210","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ibd.20177","article-title":"Infliximab dose intensification in Crohns disease.","volume":"13","author":"Regueiro","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R107-5-20210210","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease.","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"R109-5-20210210","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cgh.2010.03.024","article-title":"Reinduction with certolizumab pegol in patients with relapsed Crohns disease: Results from the PRECiSE 4 study.","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R111-5-20210210","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohns disease: results of the ENCORE Trial.","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"R112-5-20210210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1572-0241.2005.40647.x","article-title":"Safety and efficacy of adalimumab (D2E7) in Crohns disease patients with an attenuated response to infliximab.","volume":"100","author":"Papadakis","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R113-5-20210210","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1572-0241.2004.40462.x","article-title":"An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to IFX for Crohns disease.","volume":"99","author":"Sandborn","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"RU117-5-20210210","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. Crohns Disease cA2 Study Group.","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"RU118-5-20210210","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohns disease.","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"RU119-5-20210210","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohns disease.","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"RU120-5-20210210","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","article-title":"ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohns disease: response to infliximab in the ACCENT II Study.","volume":"2","author":"Sands","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"RU121-5-20210210","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC II trial.","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"RU122-5-20210210","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/ajg.2010.78","article-title":"Increased response and remission rates in short-duration Crohns disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.","volume":"105","author":"Schreiber","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"RU123-5-20210210","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/j.1572-0241.2000.03366.x","article-title":"Clinical experience with infliximab therapy in 100 patients with Crohns disease.","volume":"95","author":"Farrell","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"RU124-5-20210210","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1111\/j.1572-0241.2000.03363.x","article-title":"Infliximab in Crohns disease: first anniversary clinical experience.","volume":"95","author":"Cohen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"RU125-5-20210210","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","article-title":"Infliximab for Crohns disease in clinical practice at the Mayo Clinic: the first 100 patients.","volume":"96","author":"Ricart","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"RU126-5-20210210","first-page":"608","article-title":"Immunomodulators and on demand therapy with infliximab in Crohns disease: clinical experience with 400 infusions.","volume":"98","author":"Kinney","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"RU127-5-20210210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4321\/S1130-01082004000600003","article-title":"Predictors of response to infliximab in patients with fistulizing Crohns disease.","volume":"96","author":"Luna-Chadid","year":"2004","journal-title":"Rev Esp Enferm Dig"},{"key":"RU128-5-20210210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0399-8320(05)80718-3","article-title":"Predictors of response to infliximab in luminal Crohns disease.","volume":"29","author":"Laharie","year":"2005","journal-title":"Gastroenterol Clin Biol"},{"key":"RU129-5-20210210","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.dld.2005.01.019","article-title":"Infliximab in the treatment of Crohns disease: predictors of response in an Italian multicentric open study.","volume":"37","author":"Orlando","year":"2005","journal-title":"Dig Liver Dis"},{"key":"RU130-5-20210210","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0399-8320(06)73161-X","article-title":"Efficacy of infliximab in Crohns disease. Results of a retrospective multicenter study with a 15-month follow-up.","volume":"30","author":"Poupardin","year":"2006","journal-title":"Gastroenterol Clin Biol"},{"key":"RU132-5-20210210","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10620-007-9969-z","article-title":"Long-term durability of Crohns disease treatment with infliximab.","volume":"53","author":"Rudolph","year":"2008","journal-title":"Dig Dis Sci"},{"key":"RU133-5-20210210","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/ibd.20974","article-title":"Durability of infliximab in Crohns disease: a single-center experience.","volume":"15","author":"Gonzaga","year":"2009","journal-title":"Inflamm Bowel Dis"}],"updated-by":[{"DOI":"10.1038\/ajg.2010.484","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,2,7]],"date-time":"2011-02-07T00:00:00Z","timestamp":1297036800000}}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2010392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2010392","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2010392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201102000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:34:59Z","timestamp":1786541699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201102000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2010.392","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}